162 related articles for article (PubMed ID: 27565486)
1. [Comparison of two insulin glargine formulations: biosimilar vs. reference product].
Mönnig E; Schloot N; Hohberg C; Wiesner T; Heinemann L
MMW Fortschr Med; 2016 Aug; 158 Suppl 5():19-27. PubMed ID: 27565486
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR
Byrd RA; Owens RA; Blackbourne JL; Coutant DE; Farmen MW; Michael MD; Moyers JS; Schultze AE; Sievert MK; Tripathi NK; Vahle JL
Regul Toxicol Pharmacol; 2017 Aug; 88():56-65. PubMed ID: 28526658
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ
Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine.
Hadjiyianni I; Dahl D; Lacaya LB; Pollom RK; Chang CL; Ilag LL
Diabetes Obes Metab; 2016 Apr; 18(4):425-9. PubMed ID: 26749289
[TBL] [Abstract][Full Text] [Related]
5. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).
Rosenstock J; Hollander P; Bhargava A; Ilag LL; Pollom RK; Zielonka JS; Huster WJ; Prince MJ
Diabetes Obes Metab; 2015 Aug; 17(8):734-41. PubMed ID: 25931141
[TBL] [Abstract][Full Text] [Related]
6. LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes.
Lamb YN; Syed YY
BioDrugs; 2018 Feb; 32(1):91-98. PubMed ID: 29368288
[TBL] [Abstract][Full Text] [Related]
7. Lilly Insulin Glargine Versus Lantus
Mohan V; Ahn KJ; Cho YM; Sahay RK; Huang CN; Kalra S; Chadha M; Bhattacharya I; Kim SY; Spaepen E
Clin Drug Investig; 2019 Aug; 39(8):745-756. PubMed ID: 31119716
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.
Blevins TC; Dahl D; Rosenstock J; Ilag LL; Huster WJ; Zielonka JS; Pollom RK; Prince MJ
Diabetes Obes Metab; 2015 Aug; 17(8):726-33. PubMed ID: 25974640
[TBL] [Abstract][Full Text] [Related]
9. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.
Linnebjerg H; Lam EC; Zhang X; Seger ME; Coutant D; Chua L; Kapitza C; Heise T
Diabetes Obes Metab; 2017 Jan; 19(1):33-39. PubMed ID: 27484286
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial.
Feng W; Chen W; Jiang S; Du L; Zhu D
Diabetes Obes Metab; 2021 Aug; 23(8):1786-1794. PubMed ID: 33783964
[TBL] [Abstract][Full Text] [Related]
11. LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.
Zhang X; Lam ECQ; Seger ME; Coutant D; Chua L; Tan LH; Soon D; Linnebjerg H
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):556-563. PubMed ID: 28940840
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus.
Wang W; Song X; Lou Y; Du L; Zhu D; Zhou Z
Diabetes Obes Metab; 2022 Jun; 24(6):1094-1104. PubMed ID: 35187770
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus
Yan X; Feng C; Lou Y; Zhou Z
Diabetes Ther; 2022 Jun; 13(6):1161-1174. PubMed ID: 35471721
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies.
Linnebjerg H; Lam EC; Seger ME; Coutant D; Chua L; Chong CL; Ferreira MM; Soon D; Zhang X
Diabetes Care; 2015 Dec; 38(12):2226-33. PubMed ID: 26307603
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study.
Derwahl KM; Bailey TS; Wernicke-Panten K; Ping L; Pierre S
Diabetes Technol Ther; 2018 Jan; 20(1):49-58. PubMed ID: 29232162
[TBL] [Abstract][Full Text] [Related]
16. [LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union].
Altman JJ; Chevalier N; Delemer B; Travert F; Benabbad I
Presse Med; 2018 Oct; 47(10):854-866. PubMed ID: 30262205
[TBL] [Abstract][Full Text] [Related]
17. MYL1501D Insulin Glargine: A Review in Diabetes Mellitus.
Hoy SM
BioDrugs; 2020 Apr; 34(2):245-251. PubMed ID: 32215829
[TBL] [Abstract][Full Text] [Related]
18. Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.
Sun B; Sengupta N; Rao A; Donnelly C; Waichale V; Roy AS; Ramaswamy S; Pathak D; Bowsher RR; Raiter Y; Aubonnet P; Barve A
BMC Endocr Disord; 2021 Jun; 21(1):129. PubMed ID: 34174848
[TBL] [Abstract][Full Text] [Related]
19. Similar Efficacy and Safety of Basaglar
Pollom RK; Costigan T; Lacaya LB; Ilag LL; Hollander PA
Diabetes Ther; 2018 Apr; 9(2):827-837. PubMed ID: 29542012
[TBL] [Abstract][Full Text] [Related]
20. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
Aso Y; Suzuki K; Chiba Y; Sato M; Fujita N; Takada Y; Murano S; Kuroda H
Diabetes Res Clin Pract; 2017 Aug; 130():237-243. PubMed ID: 28651211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
